Navigation Links
Gerresheimer Further Increases its Sales and Earnings Power
Date:7/15/2008

Sales in the Second Quarter up by 12.8% to EUR276.3m (First Half: up by

15.2% to EUR515.4m)

Adjusted Group Results in the Second Quarter Tripled From EUR6.3m to

EUR17.6m

CEO Dr. Axel Herberg Confirms the Prospects for 2008

DUSSELDORF, Germany, July 15 /PRNewswire-FirstCall/ -- Gerresheimer AG again increased its sales and results in the second quarter of 2008. Compared with the second quarter of 2007, sales improved by 12.8%, or 16.5% on a like-for-like exchange-rate basis, to EUR276.3m. Operating results (Adjusted EBITDA) rose by 20.2% to EUR53.6m (second quarter of 2007: EUR44.6m). In the second quarter of 2008 Gerresheimer therefore achieved an adjusted EBITDA margin of 19.4% (second quarter of 2007: 18.2%). Contributions to this gratifying development were made by the positive sales trend in the market segments of pharmaceutics and cosmetics and by the latest acquisitions. Overall, Gerresheimer therefore continued the improvement in its earnings position in the second quarter and thus the first half of 2008 as a whole. Adjusted Group results increased in the second quarter of 2008 to EUR17.6m and in the first half to EUR27.5m. This means a three-fold rise and means adjusted earnings per share of EUR0.53 in the second quarter and EUR0.82 for the first half of 2008.

"Following our record year in 2007 we have again increased our sales and profit in the first half of 2008," says Dr. Axel Herberg, CEO of Gerresheimer AG. "We expect further growth in all divisions during the course of the year and will consistently continue to focus on pharma & life science."

Just recently, Gerresheimer's discontinuation of peripheral operations such as consumer health care confirmed this concentration on pharmaceutics and life science.

Thanks to the positive development in the second quarter a marked improvement in results has also been achieved for the first half of
'/>"/>

SOURCE Gerresheimer AG
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Yves Lionel Assant is New Chairman of Gerresheimers Supervisory Board
2. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
3. Gerresheimer: Record Year in 2007 and Positive Outlook for 2008
4. Moodys Raises Rating for Gerresheimer
5. Gerresheimer Discontinues Marginal Operations
6. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
7. China Sky One Medical Receives $1.5 Million Government Grant to Further Develop Six New Cancer Products
8. VaxGen Further Restructures to Preserve Cash as It Pursues Strategic Initiatives
9. Monitorforhire.com Adds Mobile Phone Capability Further Speeding Access to Experienced Monitors
10. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
11. Organons Asenapine Further Demonstrates Efficacy in Reducing Mania Symptoms for the Treatment of Bipolar I Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 Global ... developing innovative information technology solutions for patients, physicians, ... care stakeholders, announced today the signing of a ... Food and Drug Administration (FDA). This initiative ...
(Date:1/14/2014)... UK (PRWEB) January 13, 2014 Bob ... with more than 20 years in the industry, has ... photonics . Hainsey will serve as the society’s Science ... Dr. Hainsey join SPIE as our Technology Strategist, further ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... AB, the Swedish,life science technology company, has ... based on supercritical fluid technology.,The Company,s RightSize ... of traditional micronization and is well suited ... the advantages of earlier supercritical,fluid technologies it ...
... As researchers push towards detection of single molecules, single ... movement, Yale researchers have demonstrated silicon-based nanocantilevers, smaller than ... eliminating the need for electric transducers and expensive laser ... advance online publication of Nature Nanotechnology ushers ...
... CITY, China, April 24 Sinobiopharma, Inc. (OTC Bulletin ... highlights from the unaudited financial results for the nine month period ... , Sales revenue increased to ... US $1,170,677 in the corresponding period ended February 29, 2008. ...
Cached Biology Technology:Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 2Xspray Expands to Meet Pharma's Interest in its Ground-Breaking Particle Production Technology 3Catching the lightwave: Nano-mechanical sensors 'wired' by photonics 2Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009 2
(Date:4/17/2014)... Foundation has been named awardee of a three-year ... Defense Spinal Cord Injury Research Program. Gail Forrest, ... double-blinded, controlled, multi-site clinical trial, which will test ... spinal cord injury. Dr. Forrest is assistant director ... Foundation. Two additional sites will participate - the ...
(Date:4/17/2014)... births, Down syndrome - or trisomy 21 - is ... results from a chromosomal abnormality where cells of affected ... of the human genome). A study conducted by Stylianos ... Medicine and Development at the University of Geneva (UNIGE) ... light on how the extra chromosome 21 upsets the ...
(Date:4/17/2014)... One day about eight years ago, Katia ... Riverside, and her father were on a field trip in ... an orchid they had never seen before. , Unable to ... orchids. The orchid turned out to be an unnamed ... Lophiaris silverarum . , "Lophiaris" is the genus name, comprising ...
Breaking Biology News(10 mins):Kessler Foundation awarded Department of Defense grant for spinal cord injury research 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 2Trisomy 21: How an extra little chromosome throws the entire genome off balance 3Orchid named after UC Riverside researcher 2Orchid named after UC Riverside researcher 3
... a current issue in neuroscience, Aldo Faisal and Simon Laughlin ... transmitting information. They show that noise effects in ion channels ... the fidelity of transmission is compromised. , Neurons in ... density of up to 4km per mm3 by using incredibly ...
... A naturally occurring molecule in the body appears to ... agonists used in acute heart failure or in inhalers ... oxide is a molecule produced by the body that ... blood vessels. , New experiments conducted by Duke ...
... The first clinical trial to test a revolutionary treatment ... at UCL (University College London). The trial, funded by ... kind and could have a significant impact on future ... involves adults and children who have a condition called ...
Cached Biology News:Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 2Nitric oxide: Key to cardiovascular and pulmonary function and drug effectiveness 3First clinical trial of gene therapy for childhood blindness 2
... Sample Preparation for Membrane Proteins ,Contains ... membrane,protein extracts for 2-D gel analysis ... Extraction Kit , (contains sufficient ... a packed cell weight of 10 mg ...
...
Rabbit polyclonal to MCP2 ( Abpromise for all tested applications). entrezGeneID: 6355 SwissProtID: P49873...
... polystyrene with frosted labeling surfaces, volume ... counting. 100% integrity tested. Linkage: This ... number, created to easily match Cornings ... yet, please order under the old ...
Biology Products: